MCLEAN, Va., July 31, 2013 /PRNewswire-USNewswire/ -- Today, leading nonprofit patient advocacy and education organization Allergy & Asthma Network Mothers of Asthmatics (AANMA) released results of a survey regarding patient use of intranasal corticosteroid sprays. Findings were shared during the Food and Drug Administration (FDA) Nonprescription Drug Advisory Committee meeting considering the switch of triamcinolone nasal spray from prescription to over-the-counter status.
"AANMA conducted a survey of more than 1,600 families and patients who use nasal corticosteroid sprays and found that they are prescribed to treat a complex set of symptoms for patients who often take an assortment of other medications," says Nancy Sander, president and founder of AANMA and a nationally recognized patient advocate. "This makes patient education a high priority for safe use. When medications are available over-the-counter, families tell us they assume it is safe to self-diagnose their conditions and pick and choose among medications."
Nine out of 10 said they prefer to rely on medical professionals to diagnose and manage their conditions. When asked if intranasal corticosteroid sprays should be available without a prescription, the overwhelming concerns expressed were about cost: 72 percent felt moving the medication OTC would increase their financial burden.
"The truth is," Sander continues, "the average patient doesn't know allergic from non-allergic rhinitis, or boggy nasal passages from sinus infections or a deviated septum. These are complex conditions, and intranasal corticosteroids are serious medications with the potential for unwanted side effects. Patients deserve the best possible care and guidance from their physicians; they should not be left on their own to self-diagnose at the pharmacy."
AANMA has identified seven important facts patients should understand regarding th
|SOURCE Allergy & Asthma Network Mothers of Asthmatics|
Copyright©2012 PR Newswire.
All rights reserved